Literature DB >> 16283533

Conditioning on certain random events associated with statistical variability in PK/PD.

Stuart L Beal1.   

Abstract

In PK/PD data analysis, statistical models involving random variables are developed. At times an analysis can be carried out by conditioning on certain random events involving these variables. This paper attempts to clarify issues regarding conditioning. In particular, conditioning is examined as it relates to a number of disparate practical matters: missing covariate values, dose titration, BQL data, "no change from baseline" data, and the use of a truncated intraindividual probability distribution for PK observations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16283533     DOI: 10.1007/s10928-005-0090-7

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  7 in total

1.  The need for mixed-effects modeling with population dichotomous data.

Authors:  I Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

2.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

3.  Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

4.  Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.

Authors:  M O Karlsson; E N Jonsson; C G Wiltse; J R Wade
Journal:  J Pharmacokinet Biopharm       Date:  1998-04

5.  A simulation study comparing designs for dose ranging.

Authors:  L B Sheiner; Y Hashimoto; S L Beal
Journal:  Stat Med       Date:  1991-03       Impact factor: 2.373

6.  A two-part mixture model for longitudinal adverse event severity data.

Authors:  Kenneth G Kowalski; Lynn McFadyen; Matthew M Hutmacher; Bill Frame; Raymond Miller
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-10       Impact factor: 2.745

7.  Study designs for dose-ranging.

Authors:  L B Sheiner; S L Beal; N C Sambol
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875

  7 in total
  5 in total

1.  Impact of censoring data below an arbitrary quantification limit on structural model misspecification.

Authors:  Wonkyung Byon; Courtney V Fletcher; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-26       Impact factor: 2.745

2.  Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.

Authors:  Julie Bertrand; Emmanuelle Comets; France Mentre
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

3.  A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate.

Authors:  Chuanpu Hu; Zhenhua Xu; Mahboob U Rahman; Hugh M Davis; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-16       Impact factor: 2.745

4.  Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder.

Authors:  Bill Frame; Raymond Miller; Matthew M Hutmacher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-08       Impact factor: 2.745

5.  Mixed effects modeling of weight change associated with placebo and pregabalin administration.

Authors:  Bill Frame; Stuart L Beal; Raymond Miller; Jeannette Barrett; Paula Burger
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-08-10       Impact factor: 2.410

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.